外用薬CDMO市場規模、シェア、動向分析レポート：製品タイプ別、サービスタイプ別、最終用途別、地域別、セグメント別予測、2024-2030年

外用薬CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の外用薬CDMO市場規模は2030年までに878億8,000万米ドルに達すると予測されています。

同市場は2024年から2030年にかけてCAGR 11.4％で成長すると予測されています。様々な皮膚関連疾患や皮膚科疾患に対処するための特殊な外用薬に対するニーズが高まっています。ヘルスケアプロバイダーや患者はカスタマイズされたソリューションを求めており、外用薬に特化した専門知識を有するCDMOに対する需要の高まりにつながっています。

市場は断片化されており、複数の企業が同様の技術力と加工能力を有しています。マイクロエマルション、ナノテクノロジー、経皮パッチなどの革新的なドラッグデリバリー技術の開発により、CDMOの能力は、より患者にやさしく効果的な外用医薬品を開発する能力を高めています。さらに、個別化医療に向けた動向の高まりは、外用薬CDMOの需要を大幅に押し上げています。CDMOは、外用薬治療を個々の患者の状態やニーズに合わせて個別化する上で基本的な役割を果たすからです。

CDMOと製薬企業とのコラボレーションが増加し、CDMOは革新的で新しい外用薬の製造と開発に貢献しています。製薬会社は、研究、流通、マーケティングなどのコアコンピタンスに集中する一方で、製造サービスを専門のCDMOに委託する目的で、アウトソーシングを選択することが多いです。外用薬のFDA承認や製品上市の増加は、外用薬製造専門のCDMOの成長に大きく寄与しています。例えば、2022年5月、ダーマバント・サイエンシズは、成人の尋常性乾癬の局所管理用のVTAMA（タピナロフ）クリーム1％の米国食品医薬品局（FDA）の承認を取得しました。

COVID-19パンデミックは市場にマイナスの影響を与えました。パンデミックは世界のサプライチェーンを大きく混乱させ、製造能力や原材料の入手に影響を与えました。外用薬を含むいくつかの臨床試験は、安全性への懸念から一時的に延期または保留されました。このため、新しい外用薬治療や製剤の試験・開発が妨げられました。しかし、買収や専門医薬品プロバイダーとの提携といった戦略的イニシアチブを採用することで、業界は2021年までに市場シェアを回復しました。

外用薬CDMO市場レポートハイライト

• 製品タイプ別では、半固形製剤分野が2023年に66.2%の最大売上シェアを占めました。同分野は、クリーム、ゲル、軟膏の需要拡大と、外用薬を含む臨床試験の増加によって牽引されています。一方、クリームのサブカテゴリーは、いくつかの病状に対する外用クリームの承認が増加しているため、大きなシェアを占めています。
• サービスタイプに基づくと、受託製造セグメントは2023年に63.9%の最大の売上シェアを占めました。同分野のシェアが高いのは、主に製造委託の費用対効果に後押しされ、製造委託サービスへの需要が高まっているためです。
• 最終用途別では、外用薬の開発に関連する研究開発活動への注目が高まっていることから、バイオ製薬企業分野が予測期間中に11.6%のCAGRを記録すると予測されています。
• アジア太平洋地域は予測期間中に12.2%のCAGRを記録すると予測されています。同地域の大幅な成長は、主にアジアのいくつかの経済圏で人件費と運営コストが低いため、外用薬の製造が費用対効果に優れていることに起因しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 外用薬CDMO市場変数、動向および範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場の見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 外用薬CDMO市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19感染症の影響分析

第4章 外用薬CDMO市場：製品タイプの推定・動向分析

• 外用薬CDMO市場、製品タイプ別：セグメントダッシュボード
• 外用薬CDMO市場、製品タイプ別：変動分析
  • 半固体製剤
  • 液体製剤医薬品
  • 固形製剤
  • 経皮吸収製品

第5章 外用薬CDMO市場：サービスタイプの推定・動向分析

• 外用薬CDMO市場、サービスタイプ別：セグメントダッシュボード
• 外用薬CDMO市場、サービスタイプ別：変動分析
  • 受託開発
  • 受託製造

第6章 外用薬CDMO市場：最終用途の推定・動向分析

• 外用薬CDMO市場、最終用途別：セグメントダッシュボード
• 外用薬CDMO市場、最終用途別：変動分析
  • 製薬会社
  • バイオ医薬品企業
  • その他

第7章 外用薬CDMO市場：地域の推定・動向分析

• 地域市場シェア分析、2023年および2030年
• 地域市場ダッシュボード
• 世界の地域市場のスナップショット
• 北米
  • 市場推計・予測、2018～2030年
  • 米国
  • カナダ
• 欧州
  • 英国
  • ドイツ
  • フランス
  • イタリア
  • スペイン
  • デンマーク
  • スウェーデン
  • ノルウェー
• アジア太平洋地域
  • 日本
  • インド
  • 中国
  • 韓国
  • オーストラリア
  • タイ
• ラテンアメリカ
  • ブラジル
  • メキシコ
  • アルゼンチン
• 中東・アフリカ
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第8章 競合情勢

• 市場参入企業の分類
  • イノベーター
  • マーケットリーダー
  • 新興プレイヤー
  • 企業の市場シェア分析、2023年
• 企業プロファイル
  • Lubrizol Life Science
  • Cambrex Corporation
  • Contract Pharmaceuticals Limited
  • Bora Pharmaceutical CDMO
  • Ascendia Pharmaceuticals
  • Pierre Fabre group
  • Piramal Pharma Solutions
  • DPT Laboratories, LTD
  • MedPharm Ltd
  • PCI Pharma Services

List of Tables

• Table 1 List of secondary sources
• Table 2 List of Abbreviations
• Table 3 North America Topical Drugs CDMO market, by region, 2018 - 2030 (USD Million)
• Table 4 North America Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 5 North America Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 6 North America Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 7 North America Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 8 U.S. Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 9 U.S. Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 10 U.S. Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 11 U.S. Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 12 Canada Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 13 Canada Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 14 Canada Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 15 Canada Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 16 Europe Topical Drugs CDMO market, by region, 2018 - 2030 (USD Million)
• Table 17 Europe Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 18 Europe Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 19 Europe Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 20 Europe Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 21 UK Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 22 UK Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 23 UK Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 24 UK Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 25 Germany Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 26 Germany Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 27 Germany Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 28 Germany Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 29 France Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 30 France Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 31 France Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 32 France Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 33 Italy Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 34 Italy Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 35 Italy Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 36 Italy Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 37 Spain Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 38 Spain Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 39 Spain Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 40 Spain Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 41 Denmark Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 42 Denmark Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 43 Denmark Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 44 Denmark Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 45 Sweden Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 46 Sweden Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 47 Sweden Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 48 Sweden Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 49 Norway Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 50 Norway Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 51 Norway Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 52 Norway Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 53 Asia Pacific Topical Drugs CDMO market, by region, 2018 - 2030 (USD Million)
• Table 54 Asia Pacific Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 55 Asia Pacific Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 56 Asia Pacific Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 57 Asia Pacific Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 58 China Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 59 China Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 60 China Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 61 China Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 62 Japan Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 63 Japan Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 64 Japan Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 65 Japan Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 66 India Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 67 India Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 68 India Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 69 India Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 70 Australia Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 71 Australia Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 72 Australia Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 73 Australia Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 74 South Korea Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 75 South Korea Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 76 South Korea Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 77 South Korea Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 78 Thailand Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 79 Thailand Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 80 Thailand Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 81 Thailand Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 82 Latin America Topical Drugs CDMO market, by region, 2018 - 2030 (USD Million)
• Table 83 Latin America Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 84 Latin America Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 85 Latin America Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 86 Latin America Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 87 Brazil Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 88 Brazil Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 89 Brazil Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 90 Brazil Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 91 Mexico Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 92 Mexico Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 93 Mexico Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 94 Mexico Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 95 Argentina Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 96 Argentina Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 97 Argentina Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 98 Argentina Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 99 Middle East and Africa Topical Drugs CDMO market, by region, 2018 - 2030 (USD Million)
• Table 100 Middle East and Africa Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 101 Middle East and Africa Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 102 Middle East & Africa Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 103 Middle East and Africa Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 104 South Africa Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 105 South Africa Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 106 South Africa Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 107 South Africa Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 108 Saudi Arabia Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 109 Saudi Arabia Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 110 Saudi Arabia Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 111 Saudi Arabia Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 112 UAE Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 113 UAE Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 114 UAE Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 115 UAE Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)
• Table 116 Kuwait Topical Drugs CDMO market, by Service Type, 2018 - 2030 (USD Million)
• Table 117 Kuwait Topical Drugs CDMO market, by Product Type, 2018 - 2030 (USD Million)
• Table 118 Kuwait Topical Drugs CDMO market, by Semi-solid Formulations, 2018 - 2030 (USD Million)
• Table 119 Kuwait Topical Drugs CDMO market, by End-use, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Information procurement
• Fig. 3 Market research approaches
• Fig. 4 QFD modeling for market share assessment
• Fig. 5 Market formulation & validation
• Fig. 6 Commodity flow analysis
• Fig. 7 Primary research pattern
• Fig. 8 Primary interviews in North America
• Fig. 9 Primary interviews in Europe
• Fig. 10 Primary interviews in the Asia Pacific
• Fig. 11 Primary interviews in Latin America
• Fig. 12 Primary interviews in MEA
• Fig. 13 Market Snapshot
• Fig. 14 Segment Snapshot
• Fig. 15 Segment Snapshot
• Fig. 16 Competitive Landscape Snapshot
• Fig. 17 Topical Drugs CDMO market segmentation
• Fig. 18 Parent market outlook (2023)
• Fig. 19 Related/ancillary market outlook (2023)
• Fig. 20 Market driver relevance analysis (Current & future impact)
• Fig. 21 Market restraint relevance analysis (Current & future impact)
• Fig. 22 Porter's five forces analysis
• Fig. 23 SWOT analysis, by a factor (political & legal, economic and technological)
• Fig. 24 Topical Drugs CDMO Market Product Type outlook: Segment dashboard
• Fig. 25 Topical Drugs CDMO: Product Type movement analysis
• Fig. 26 Semi-solid Formulations market, 2018 - 2030 (USD Million)
• Fig. 27 Creams market, 2018 - 2030 (USD Million)
• Fig. 28 Ointments market, 2018 - 2030 (USD Million)
• Fig. 29 Gel market, 2018 - 2030 (USD Million)
• Fig. 30 Others market, 2018 - 2030 (USD Million)
• Fig. 31 Liquid Formulations Drugs market, 2018 - 2030 (USD Million)
• Fig. 32 Solid Formulations market, 2018 - 2030 (USD Million)
• Fig. 33 Transdermal Products market, 2018 - 2030 (USD Million)
• Fig. 34 Topical Drugs CDMO Market Service Type outlook: Segment dashboard
• Fig. 35 Topical Drugs CDMO: Service Type type movement analysis
• Fig. 36 Contract Development market, 2018 - 2030 (USD Million)
• Fig. 37 Contract Manufacturing market, 2018 - 2030 (USD Million)
• Fig. 38 Topical Drugs CDMO market End-use outlook: Segment dashboard
• Fig. 39 Topical Drugs CDMO market: End-use movement analysis
• Fig. 40 Pharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 41 Biopharmaceutical Companies market, 2018 - 2030 (USD Million)
• Fig. 42 Others market, 2018 - 2030 (USD Million)
• Fig. 43 Regional marketplace: Segment dashboard
• Fig. 44 Regional outlook, 2023 & 2030
• Fig. 45 North America market, 2018 - 2030 (USD Million)
• Fig. 46 U.S. market, 2018 - 2030 (USD Million)
• Fig. 47 Canada market, 2018 - 2030 (USD Million)
• Fig. 48 Europe market, 2018 - 2030 (USD Million)
• Fig. 49 Germany market, 2018 - 2030 (USD Million)
• Fig. 50 UK market, 2018 - 2030 (USD Million)
• Fig. 51 France market, 2018 - 2030 (USD Million)
• Fig. 52 Italy market, 2018 - 2030 (USD Million)
• Fig. 53 Spain market, 2018 - 2030 (USD Million)
• Fig. 54 Denmark market, 2018 - 2030(USD Million)
• Fig. 55 Sweden market, 2018 - 2030 (USD Million)
• Fig. 56 Norway market, 2018 - 2030 (USD Million)
• Fig. 57 Asia Pacific market, 2018 - 2030 (USD Million)
• Fig. 58 China market, 2018 - 2030 (USD Million)
• Fig. 59 Japan market, 2018 - 2030 (USD Million)
• Fig. 60 India market, 2018 - 2030 (USD Million)
• Fig. 61 Australia market, 2018 - 2030 (USD Million)
• Fig. 62 South Korea market, 2018 - 2030 (USD Million)
• Fig. 63 Thailand market, 2018 - 2030 (USD Million)
• Fig. 64 Latin America market, 2018 - 2030 (USD Million)
• Fig. 65 Brazil market, 2018 - 2030 (USD Million)
• Fig. 66 Mexico market, 2018 - 2030 (USD Million)
• Fig. 67 Argentina market, 2018 - 2030 (USD Million)
• Fig. 68 Middle East & Africa market, 2018 - 2030 (USD Million)
• Fig. 69 South Africa market, 2018 - 2030 (USD Million)
• Fig. 70 Saudi Arabia market, 2018 - 2030 (USD Million)
• Fig. 71 UAE market, 2018 - 2030 (USD Million)
• Fig. 72 Kuwait market, 2018 - 2030 (USD Million) 

Topical Drugs CDMO Market Growth & Trends:

The global topical drugs CDMO market size is expected to reach USD 87.88 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 11.4% from 2024 to 2030. There is an increasing need for specialized topical drugs to address various skin-related and dermatological conditions. Healthcare providers and patients seek customized solutions, leading to a rise in demand for CDMOs with specialized expertise in topical drugs.

The market is fragmented, with several players having similar technological and processing capabilities. The development of innovative drug delivery technologies, such as microemulsions, nanotechnology, and transdermal patches, has extended the abilities of CDMOs to create more patient-friendly and effective topical drug products. Furthermore, a growing trend towards personalized medicine has significantly boosted demand for topical drug CDMOs, as they play a fundamental role in personalizing topical treatments to individual patient conditions and needs.

Collaborations between CDMOs and pharmaceutical companies have risen, with CDMOs contributing to the manufacturing and development of innovative and new topical drugs. Pharmaceutical firms significantly opt for outsourcing with an aim to focus on core competencies such as research, distribution, and marketing while entrusting manufacturing services to dedicated CDMOs. The increasing number of FDA approvals and product launches in topical medications significantly contributes to CDMOs specializing in topical drug manufacturing growth. For instance, in May 2022, Dermavant Sciences received the U.S. Food and Drug Administration (FDA) approval for its VTAMA (tapinarof) cream, 1%, for the topical management of plaque psoriasis in adults.

The COVID-19 pandemic negatively impacted the market. The pandemic has significantly disrupted the global supply chains, affecting the accessibility of manufacturing capabilities and raw materials. Several clinical studies, including those for topical medicine, were temporarily delayed or put on hold owing to safety concerns. This disturbed the testing and development of new topical drug treatments and formulations. However, by adopting strategic initiatives such as acquisition and partnerships with specialized drug providers, the industry regained its market shares by 2021.

Topical Drugs CDMO Market Report Highlights:

• Based on product type, the semi-solid formulations segment held the largest revenue share of 66.2% in 2023.The segment is driven by the growing demand for creams, gels, and ointments and the rise in clinical trials involving topical drugs. The cream sub-category, on the other hand, held the lion's share owing to increasing approval of topical creams for several medical conditions
• Based on the service type, the contract manufacturing segment held the largest revenue share of 63.9% in 2023. The high shares of the segment are majorly due to the growing demand for outsourced manufacturing services, driven by the cost-effectiveness of outsourced manufacturing
• In terms of end-use, the biopharmaceutical companies segment is anticipated to witness the fastest CAGR of 11.6% over the forecast period owing to the rise in focus on R&D activities pertaining to the development of topical medication
• Asia Pacific is anticipated to register the fastest CAGR of 12.2% over the forecast period. The region's substantial growth is primarily attributed to the cost-effective manufacturing of topical products due to lower labor and operational costs in several Asian economies

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
  • 1.1.2. Product Type
  • 1.1.3. Service Type
  • 1.1.4. End-use
• 1.2. Regional Scope
• 1.3. Estimates And Forecast Timeline
• 1.4. Objectives
  • 1.4.1. Objective-1
  • 1.4.2. Objective-2
  • 1.4.3. Objective-3
• 1.5. Research Methodology
• 1.6. Information Procurement
  • 1.6.1. Purchased Database
  • 1.6.2. GVR's Internal Database
  • 1.6.3. Secondary Sources
  • 1.6.4. Primary Research
• 1.7. Information Or Data Analysis
  • 1.7.1. Data Analysis Models
• 1.8. Market Formulation & Validation
• 1.9. Model Details
  • 1.9.1. Commodity Flow Analysis
  • 1.9.2. Parent Market Analysis
• 1.10. List Of Secondary Sources
• 1.11. List Of Abbreviations

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Topical Drugs CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. High demand for non-invasive treatment options to boost sales of topical drugs
    • 3.2.1.2. Growing pipeline of topical drugs
    • 3.2.1.3. Growing research and development investments
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Compliance with strict regulatory requirements
    • 3.2.2.2. Limited efficacy in certain conditions limits adoption of topical products
• 3.3. Topical Drugs CDMO Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat Of New Entrant
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTEL Analysis
  • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Topical Drugs CDMO Market: Product Type Estimates & Trend Analysis

• 4.1. Topical Drugs CDMO Market, By Product Type: Segment Dashboard
• 4.2. Topical Drugs CDMO Market, By Product Type: Movement Analysis
• 4.3. Topical Drugs CDMO Market Estimates & Forecasts, By Product Type, 2018 - 2030
  • 4.3.1. Semi-solid Formulations
    • 4.3.1.1. Semi-solid Formulations Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.1.2. Creams
    • 4.3.1.2.1. Creams Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.1.3. Ointments
    • 4.3.1.3.1. Ointments Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.1.4. Gel
    • 4.3.1.4.1. Gel Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
    • 4.3.1.5. Others
    • 4.3.1.5.1. Others Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
  • 4.3.2. Liquid Formulations Drugs
    • 4.3.2.1. Liquid Formulations Drugs Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
  • 4.3.3. Solid Formulations
    • 4.3.3.1. Solid Formulations Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
  • 4.3.4. Transdermal Products
    • 4.3.4.1. Transdermal Products Topical Drugs CDMO Market, 2018 to 2030 (USD Million)

Chapter 5. Topical Drugs CDMO Market: Service Type Estimates & Trend Analysis

• 5.1. Topical Drugs CDMO Market, By Service Type: Segment Dashboard
• 5.2. Topical Drugs CDMO Market, By Service Type: Movement Analysis
• 5.3. Topical Drugs CDMO Market Estimates & Forecasts, By Service Type, 2018 - 2030
  • 5.3.1. Contract Development
    • 5.3.1.1. Contract Development Topical Drugs CDMO Market, 2018 to 2030 (USD Million)
  • 5.3.2. Contract Manufacturing
    • 5.3.2.1. Contract Manufacturing Topical Drugs CDMO Market, 2018 to 2030 (USD Million)

Chapter 6. Topical Drugs CDMO Market: End-use Estimates & Trend Analysis

• 6.1. Topical Drugs CDMO Market, By End-use: Segment Dashboard
• 6.2. Topical Drugs CDMO Market, By End-use: Movement Analysis
• 6.3. Topical Drugs CDMO Market Estimates & Forecasts, By End-use, 2018 - 2030
  • 6.3.1. Pharmaceutical Companies
    • 6.3.1.1. Pharmaceutical Companies Topical Drugs CDMO Market 2018 to 2030 (USD Million)
  • 6.3.2. Biopharmaceutical Companies
    • 6.3.2.1. Biopharmaceutical Companies Topical Drugs CDMO Market 2018 to 2030 (USD Million)
  • 6.3.3. Others
    • 6.3.3.1. Others Topical Drugs CDMO Market 2018 to 2030 (USD Million)

Chapter 7. Topical Drugs CDMO Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2023 & 2030
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. North America
  • 7.4.1. Market Estimates and Forecast, 2018 - 2030 (Revenue, USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030
• 7.5. Europe
  • 7.5.1. UK
    • 7.5.1.1. Key Country Dynamics
    • 7.5.1.2. Competitive Scenario
    • 7.5.1.3. Regulatory Framework
    • 7.5.1.4. UK Market Estimates and Forecasts, 2018 - 2030
  • 7.5.2. Germany
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Germany Market Estimates and Forecasts, 2018 - 2030
  • 7.5.3. France
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. France Market Estimates and Forecasts, 2018 - 2030
  • 7.5.4. Italy
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Italy Market Estimates and Forecasts, 2018 - 2030
  • 7.5.5. Spain
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Spain Market Estimates and Forecasts, 2018 - 2030
  • 7.5.6. Denmark
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Denmark Market Estimates and Forecasts, 2018 - 2030
  • 7.5.7. Sweden
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Sweden Market Estimates and Forecasts, 2018 - 2030
  • 7.5.8. Norway
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Norway Market Estimates and Forecasts, 2018 - 2030
• 7.6. Asia Pacific
  • 7.6.1. Japan
    • 7.6.1.1. Key Country Dynamics
    • 7.6.1.2. Competitive Scenario
    • 7.6.1.3. Regulatory Framework
    • 7.6.1.4. Japan Market Estimates and Forecasts, 2018 - 2030
  • 7.6.2. India
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. India Market Estimates and Forecasts, 2018 - 2030
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. China Market Estimates and Forecasts, 2018 - 2030
  • 7.6.4. South Korea
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. South Korea Market Estimates and Forecasts, 2018 - 2030
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Australia Market Estimates and Forecasts, 2018 - 2030
  • 7.6.6. Thailand
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Thailand Market Estimates and Forecasts, 2018 - 2030
• 7.7. Latin America
  • 7.7.1. Brazil
    • 7.7.1.1. Key Country Dynamics
    • 7.7.1.2. Competitive Scenario
    • 7.7.1.3. Regulatory Framework
    • 7.7.1.4. Brazil Market Estimates and Forecasts, 2018 - 2030
  • 7.7.2. Mexico
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Mexico Market Estimates and Forecasts, 2018 - 2030
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030
• 7.8. MEA
  • 7.8.1. South Africa
    • 7.8.1.1. Key Country Dynamics
    • 7.8.1.2. Competitive Scenario
    • 7.8.1.3. Regulatory Framework
    • 7.8.1.4. South Africa Market Estimates and Forecasts, 2018 - 2030
  • 7.8.2. Saudi Arabia
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030
  • 7.8.3. UAE
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. UAE Market Estimates and Forecasts, 2018 - 2030
  • 7.8.4. Kuwait
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Kuwait Market Estimates and Forecasts, 2018 - 2030

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
  • 8.1.1. Innovators
  • 8.1.2. Market Leaders
  • 8.1.3. Emerging Players
  • 8.1.4. Company Market Share Analysis, 2023
• 8.2. Company Profiles
  • 8.2.1. Lubrizol Life Science
    • 8.2.1.1. Company Overview
    • 8.2.1.2. Financial Performance
    • 8.2.1.3. Service Benchmarking
    • 8.2.1.4. Strategic Initiatives
  • 8.2.2. Cambrex Corporation
    • 8.2.2.1. Company Overview
    • 8.2.2.2. Financial Performance
    • 8.2.2.3. Service Benchmarking
    • 8.2.2.4. Strategic Initiatives
  • 8.2.3. Contract Pharmaceuticals Limited
    • 8.2.3.1. Company Overview
    • 8.2.3.2. Financial Performance
    • 8.2.3.3. Service Benchmarking
    • 8.2.3.4. Strategic Initiatives
  • 8.2.4. Bora Pharmaceutical CDMO
    • 8.2.4.1. Company Overview
    • 8.2.4.2. Financial Performance
    • 8.2.4.3. Service Benchmarking
    • 8.2.4.4. Strategic Initiatives
  • 8.2.5. Ascendia Pharmaceuticals
    • 8.2.5.1. Company Overview
    • 8.2.5.2. Financial Performance
    • 8.2.5.3. Service Benchmarking
    • 8.2.5.4. Strategic Initiatives
  • 8.2.6. Pierre Fabre group
    • 8.2.6.1. Company Overview
    • 8.2.6.2. Financial Performance
    • 8.2.6.3. Service Benchmarking
    • 8.2.6.4. Strategic Initiatives
  • 8.2.7. Piramal Pharma Solutions
    • 8.2.7.1. Company Overview
    • 8.2.7.2. Financial Performance
    • 8.2.7.3. Service Benchmarking
    • 8.2.7.4. Strategic Initiatives
  • 8.2.8. DPT Laboratories, LTD
    • 8.2.8.1. Company Overview
    • 8.2.8.2. Financial Performance
    • 8.2.8.3. Service Benchmarking
    • 8.2.8.4. Strategic Initiatives
  • 8.2.9. MedPharm Ltd
    • 8.2.9.1. Company Overview
    • 8.2.9.2. Financial Performance
    • 8.2.9.3. Service Benchmarking
    • 8.2.9.4. Strategic Initiatives
  • 8.2.10. PCI Pharma Services
    • 8.2.10.1. Company Overview
    • 8.2.10.2. Financial Performance
    • 8.2.10.3. Service Benchmarking
    • 8.2.10.4. Strategic Initiatives